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Spinal muscular atrophy (SMA) is a recessive disease caused by mutations in the SMN1 gene, 
which encodes the protein Survival Motor Neuron (SMN) whose absence dramatically affects 
the survival of motor neurons. In humans, the severity of the disease is lessened by the 
presence of a gene copy, SMN2. SMN2 differs from SMN1 by a C-to-T transition in exon 7, 
which modifies pre-mRNA splicing and prevents successful SMN synthesis. Splice-switching 
approaches using antisense oligonucleotides (AON) have already been shown to correct this 
SMN2 gene transition providing a therapeutic avenue for SMA. However, AON 
administration to the central nervous system (CNS) presents additional hurdles. In this study 
we show that systemic delivery of tricyclo-DNA (tcDNA) AON in a type III SMA mouse 
augments retention of exon 7 in SMN2 mRNA both in peripheral organs and the CNS. Mild 
type III SMA mice were selected as opposed to the severe type I model in order to test tcDNA 
efficacy and their ability to enter the CNS after maturation of the BBB. Furthermore, 
subcutaneous treatment significantly improved the necrosis phenotype and respiratory 
function. In summary, our data support that tcDNA oligomers effectively cross the blood-
brain-barrier and offer a promising systemic alternative for treating SMA. 
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Spinal muscular atrophy (SMA) is an autosomal-recessive inherited disease characterised by 
the degeneration of α-motor neurons of the anterior horn of spinal cord which leads to 
progressive muscle atrophy. It is caused by mutations in the gene SMN1 encoding the 
Survival Motor Neuron protein (SMN) and it has an incidence of about 1 in 6,000 live births.1  
SMN is a 37 kDa protein located in both the cytoplasm and the nucleus where it is 
concentrated in several intense foci referred to as Gemini of Cajal Bodies (gems).2  This 
ubiquitous protein plays an essential role in uridine-rich small nuclear ribonucleoprotein 
(snRNP) assembly in the cytoplasm,3 and also participates in snRNP importation into the 
nucleus. Once in the nucleus SMN relocates to gems, while released snRNPs accumulate in 
Cajal bodies to form part of the splicing machinery. One might expect that reduced SMN 
levels should broadly affect the processing of pre-mRNAs in all cell types, though this clearly 
does not occur in SMA patients. The neuron-specific consequences of SMA are still widely 
debated, though have been partially attributed to SMN’s role in the axonal transport of 
particular mRNAs which suggests a rationale for the prominent effect of SMN-depletion on 
spinal motor neuron survival.4 The clinical consequences of SMA range from severe to mild 
(types 1-4), tending to affect proximal muscle groups primarily, and with deleterious effects 
on respiratory function.  
In humans, the severity of disease is lessened by the presence of SMN2 (a centromeric copy of 
the gene).5 SMN2 differs from SMN1 (a telomeric copy) by only one nucleotide in the coding 
sequence: a translationally-silent C to T at position +6 (C6T) altering the splicing of exon 7. 
Consequently 10% of SMN2 pre-mRNAs are correctly spliced but 90% lack exon 7 
(SMN(Δ7)). 6, 7 Translation of respective mRNAs gives rise to a very limited amount of fully-
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functional full-length SMN protein in addition to a truncated SMNΔ7) protein which is 
rapidly degraded.8, 9 As one might expect, the severity of SMA is inversely-proportional to the 
SMN2 copy number which varies from 1 to 8 in humans;10 suggesting the potential of SMN2 
correction as a valid therapeutic strategy.  
The splicing of SMN2 exon 7 has been well characterised and requires many different 
elements including: a suboptimal intron 6 branch point; 11 an extended inhibitory context; 12, 13 
a conserved tract domain, an inhibitory 3’-cluster; 12 an intronic silencer element in intron 7 
(ISS-N1) 14 and a terminal stem-loop structure on 5’ splice site exon 7 (TSL) 15 
(Supplementary fig. S1). The particular genomic organisation of SMN genes has enabled 
novel therapeutic approaches aiming at re-including SMN2 exon 7 to produce fully-functional 
SMN protein in the absence of the SMN1 gene. This has already been achieved using 
antisense-oligonucleotide (AON) strategies aimed at: blocking the exonic splice-silencer 
generated by the C6T transition; annealing the intronic splice silencer downstream of exon 7; 
or decreasing the strength of the acceptor splice site of exon 8. 16  
Various classes of AON have been developed to modulate mRNA splicing. Oligonucleotide 
studies have shown efficient re-inclusion of SMN2 exon 7, in particular those using 
2’OMethoxyEthyl (2’MOE) with 17 mer AONs targeting ISS-N1. This particular AON 
demonstrated phenotypic rescue (ear and tail necrosis) of type III SMA mice (a mild 
phenotype) after intracerebroventricular (ICV) injection,17 and increased survival of type I 
SMA mice (a severe model) by subcutaneous injections at P0 and P3.18  Studies have also 
been conducted using phosphorodiamidate morpholino oligomer (PMO) AONs on different 
mice models using ICV injection that result in a significantly extended life-span.19, 20 
Interestingly a cumulative benefit was obtained when ICV injections were coupled with 
intraperitoneal injections (IP) further reinforcing the peripheral function of SMN in SMA 
mice, previously demonstrated by Hua and colleagues.18,21 This peripheral role of SMN 
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strongly suggests that the optimal biodistribution of AONs across tissue types is important for 
therapeutic efficacy (at least in SMA mice models).  
Notwithstanding these advances in chemistry and design, the uptake of AONs is still limited 
in many tissues including the heart and the CNS – a crucial target in SMA. This is due to the 
inability of most AONs to cross the blood-brain-barrier (BBB). Accordingly, in the majority 
of SMA animal studies and in trials for the recently U.S. Food and Drug Administration 
(FDA)-approved nusinersen (an AON targeting ISS-N1), treatment is administered via the 
intrathecal or ICV route. Despite encouraging data, these routes of administration present 
obvious clinical challenges and neglect the issue of delivery of AONs to the periphery.  
In this paper we explore the therapeutic potential of tricyclo-DNA AONs (tcDNA), a class of 
conformationally-constrained DNA analogues that display enhanced binding properties to 
DNA and RNA,22  allowing them to be designed as shorter sequences compared with 
chemistries such as 2’MOE or PMO. Moreover tcDNA were recently shown to cross the 
BBB,23  a key property which allows us to effectively evaluate the central and peripheral 
restoration of SMN following systemic delivery.  
In our study we first compare the efficacy of two different tcDNA sequences to induce exon 7 
re-inclusion in vitro. We further investigate the in vivo-efficacy of tcDNA in a mild SMA 
mouse model (type III SMA mouse) to induce exon re-inclusion in all tissues following 
systemic administration. We have selected the type III SMA mouse model in order to test 
tcDNA-AONs efficacy, and their ability to enter the CNS after maturation of the BBB.24 This 
would not have been feasible with severe type I mice which require injections around P0-P2 
because of their very short lifespan (around P10).17, 18 
After subcutaneous tcDNA treatment we show efficient exon re-inclusion in all tissues 
including the CNS, which leads to phenotypic improvement in type III SMA. Furthermore, 
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for the first time in SMA mice we describe rescue of respiratory function after treatment with 
tcDNA using whole-body plethysmography.  
 
RESULTS 
TcDNA AON effectively restores exon 7 reinclusion in SMA type-1 fibroblasts 
To evaluate the efficacy of tcDNA AONs SMA type-1 fibroblast cells (GM03813, Coriell) 
were transfected with 30µg of oligonucleotide targeting the downstream ISS-N1 site in intron 
7, thereby improving the strength of the 5’donor site (15 mer tcDNA-AON I7; henceforth 
referred to as ‘TCI7’). Total RNA from transfected fibroblasts was analysed by reverse 
transcription PCR (RT-PCR) 48h after transfection to establish the inclusion levels of SMN2 
exon 7. In TCI7-treated SMA fibroblasts the level of exon 7 inclusion was augmented to 64% 
from a baseline of 40% in untreated SMA fibroblasts (fig. 1a).  
Despite the fact that SMA type-1 fibroblasts cells have no functional SMN1 gene and only 
two copies of SMN2 gene, they still produce SMN protein generated from the two existing 
SMN2 gene copies, however, the truncated protein of the SMN2 gene is unstable and rapidly 
degraded, hampering normal cellular function. Western blot was conducted and protein levels 
were recorded as a percentage of total actin expressed by respective fibroblast cell lines 
(GM03814, Coriell) (fig. 1b, WT). Untreated SMA type-1 fibroblasts expressed 10% of SMN 
protein at 37 kDa (fig. 1b, SMAI) whereas in TCI7-treated type-1 SMA fibroblasts induced a 
significant increase of total SMN protein reaching mean levels of 90% as a proportion of total 
WT levels (fig. 1b, TCI7).  
In addition, another tcDNA oligonucleotide sequence (17 mer tcDNA-AON TSL; henceforth 
referred to as ‘TCTSL’) which anneals to the structure of terminal stem-loop (TSL; 
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supplementary fig. S1) was investigated, and analogous 2’O-Methyl compounds were 
looked at to compare their efficacies (Supplementary fig. S2). RT-PCR and western blot 
results indicate that tcDNA AONs induce higher levels of exon 7 inclusion and SMN protein 
restoration compared to 2’OMe AONs (although not statistically significant). Regarding the 
targeted region, ISS7-N1-manipulation with AONs resulted in more inclusion of exon 7 and 
SMN protein expression which prompted us to continue with this target for the remaining 
experiments.  
To assess proper localisation of SMN protein in gems immunofluorescence was used. 
Compared with fibroblasts of healthy individuals normally displaying between 52-113 
gems/100 nuclei,25 most SMA type I patient fibroblasts have very limited amounts of SMN-
containing nuclear gems (figs. 1c and 1d). To determine if TCI7 treatment increased levels of 
full-length SMN protein in its correct localisation we counted the number of gem-positive 
nuclei in treated and untreated SMA type-1 fibroblasts. As shown in figure 1c the restored 
SMN protein is correctly localised in nuclear gems in TCI7-treated fibroblasts and that the 
number of gem positive nuclei is restored to the level found in fibroblasts of healthy 
individuals (fig. 1d). 
TCI7 induces exon 7 inclusion in SMA type III mice 
Our in vivo studies were conducted using SMA type III transgenic mice which exhibit a mild 
SMA phenotype. Type III SMA mice are knocked out for murine SMN and possess 2 
transgenes comprising 2 copies of the human SMN2 gene leaving a total of 4 copies of SMN2 
genes (Smn-/-; SMN2 +/+).24  Type III SMA mice were injected subcutaneously every week 
for a period of 4 or 12 weeks with a dose of 200mg/kg of TCI7 (or PBS as a control in the 
untreated mice) and sacrificed 2 weeks post-treatment. Since an element of our enquiry is to 
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establish trans- blood-brain-barrier (BBB) efficacy, the injection of mice commenced at P7 
because at this stage of murine development the BBB already has very limited permeability. 
Mice were analyzed for exon 7 inclusion by RT-PCR in different tissues including the 
gastrocnemius, diaphragm, heart, brain, and the spinal cord (fig. 2). In untreated mice the 
percentage of exon 7 inclusion in different tissues measured approximately 30%. TCI7 
treatment significantly increased the inclusion of exon 7 in all tissues. This increase was 
particularly significant in the gastrocnemius muscle where 55% of exon 7 inclusion is 
detected after 4 weeks of treatment and 75% after 12 weeks of treatment. The degree of 
improvement was similar in diaphragm, heart and spinal cord with close to 50% inclusion 
after 4 weeks of treatment and up to 60% inclusion after 12 weeks. In brain the level of exon 
7 inclusion reached about 40% after 12 weeks of treatment.  
We also quantified by real-time quantitative RT-PCR (qRT-PCR) the level of inclusion in 
heart and brain tissue (fig. 3). In cardiac muscle qRT-PCR revealed that exon 7 inclusion was 
increased by 1.8-fold after 4 weeks of treatment and by over 2-fold after 12 weeks of 
treatment, confirming our previous semi-quantitative results. In the brain the inclusion was 
increased by 1.3 fold after 12 weeks of treatment verifying the ability of TCI7 to induce exon 
7 inclusion in this tissue type. 
TCI7 treatment is consistently sustained long-term 
To evaluate the long term effect of tcDNA treatment we also analysed exon 7 inclusion by 
RT-PCR 10 weeks after the end of a 4 week course of tcDNA treatment, comparing it with 
samples obtained 2 weeks after the end of the treatment. The level of exon 7 inclusion appears 
to be similar for the two treated groups of mice at 2 weeks or 10 weeks after the end of the 
treatment across analysed tissues, suggesting that TCI7 or its effects persist in tissues for at 
least 10 weeks and are still inducing exon inclusion (fig. 4). 
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TCI7 treatment significantly improves respiratory function in SMA mice  
SMA type III patients display respiratory dysfunction e.g. thoraco-abdominal asynchrony that 
is often caused by paralysis of the rib cage muscles in the presence of normal diaphragmatic 
activity.26 Notwithstanding, to our knowledge respiratory function has never been studied in 
SMA type III mice. We investigated respiratory function in SMA type III mice by whole-
body plethysmography, a non-invasive technique which measures various respiratory 
parameters (displayed in table 1).  Compared with age-matched wild-type control FVB mice, 
Te (expiration time), RT (relaxion time) and Penh are significantly increased in SMA type III 
mice (table 1). Some parameters are not altered in SMA type III mice such as Ti (inspiration 
time), f (breathing frequency), TV (tidal volume) and  MV (minute ventilation), consistent 
with what is  observed in patients compared vs. healthy individuals 26 (table 1). TCI7 
treatment in SMA type III mice restored RT and Te back to WT levels, suggesting that an 
increase of exon 7 inclusion to 60% in diaphragm is correlated with an improvement in 
respiratory function (fig. 5). 
TCI7 treatment halts tissue necrosis in SMA III mice 
Finally we investigated the effect of TCI7 treatment on the SMA III phenotype. SMA type III 
mice typically display progressive necrosis of tails, ears and toes.24 Tail lengths in all mice 
were measured weekly throughout the course of treatment (12 weeks). Untreated mice at 
week 12 post-treatment underwent complete tail necrosis while treated SMA mice were 
unaffected (fig. 6a,b,d). Interestingly treatment with 200 mg/kg of TCI7 for 4 weeks also 
resulted in comparable tail lengths vs. mice treated for 12 weeks (fig. 6d), suggesting that this 
phenotypic benefit is sustained long-term. Moreover none of the treated mice presented 
necrosis of toes and ears at 12 weeks of age compared to SMA controls (fig. 6b,c). A dosing 
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regimen of 100 mg/kg was also evaluated resulting in slightly shorter tails vs the mice treated 
with 200mg/kg, suggesting that the effect of TCI7 is dose-dependent (data not shown).  
 
DISCUSSION  
Splice-switching to induce SMN-reinclusion using AON is a well-established strategy for the 
treatment of SMA. As previously mentioned, an AON of the 2’OMethoxyethyl-subtype 
named nusinersen (marketed as ‘Spinraza’) has recently been approved by the FDA for the 
treatment of SMA. After positive phase I results with an improvement of the Hammersmith 
Functional Motor Scale at 3 months post treatment,27 interim analyses of phase 3 studies 
(ENDEAR and CHERISH) have demonstrated promising outcomes for patients. However, it 
is notable that nusinersen is administered intrathecally, a route of administration that is 
frequently less well-tolerated and typically requires specialist training vs. alternative routes of 
administration (e.g. subcutaneous or IV).  In a study analysing the patient experience of 
nusinersen 32% of lumbar punctures (LP) resulted in adverse events.28 Whilst the LP event 
rate in SMA patients is not shown to be higher than usually reported in children, it is 
noteworthy that all patients in this trial underwent general anaesthaesia, which is not without 
its own risks. 
CNS delivery of most AONs does not occur with systemic (e.g. intravenous or subcutaneous) 
injection. In SMA it is necessary for treatment to reach the CNS. To surmount the issue of 
AONs crossing the BBB ICV injections can be administered, or intrathecal pumps may be 
used clinically to deliver treatment to the spinal cord in patients. In the case of nusinersen 
intrathecal injection is crucial since it is unable to cross the BBB, though this neglects the 
issue of oligonucleotide penetration of peripheral tissues. It has been demonstrated several 
times (albeit in animal models) that peripheral rescue in SMA is important and that CNS 
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treatment alone is not sufficient. Whilst this phenomenon may not directly apply to human 
forms of the disease it remains an unaddressed issue.  
Consequent to these challenges we believe that an unmet need remains for an AON treatment 
in SMA which not only deals with the issue of peripheral and central tissue penetration but 
also provides a simpler route of administration which is more easily administered and better 
tolerated. Previous research in our group using a Duchenne Muscular Dystrophy mouse model 
(named mdx) has demonstrated that tcDNA is able to cross the blood brain barrier.23  Using 
tcDNA administered intravenously, mdx mice benefitted from an improvement in cardio-
respiratory function and furthermore, correction of behavioural features controlled by central 
mechanisms. Given tcDNA’s proven ability to cross the BBB whilst maintaining efficacy in 
the periphery when administered systemically, it is a strong candidate as a treatment for SMA.  
To properly investigate this intrinsic property of tcDNA in SMA we elected to use type III 
SMA mice rather than the more severe type I mouse model to allow sufficient time for 
maturation of the BBB. After successful in-vitro proof-of-concept studies in SMA patient 
fibroblast cell lines, we have shown that subcutaneous administration of TCI7 in type III 
SMA mice (at P7) induces significantly increased levels of exon 7 re-inclusion in all 
examined tissues. Importantly TCI7 penetration includes the CNS demonstrating the ability of 
tcDNA to cross the blood brain barrier. 
The TC17 splice-switching treatment improves the SMA phenotype by preventing tail, ear 
and toe necrosis, further implying therapeutic potential in SMA. It remains unclear why 
necrosis phenotypes are associated with SMA, a feature more prevalent in SMA mice than in 
human SMA phenotypes. The Hsieh-Li-model used here presents with necrosis of the tail, 
ears and toes, and many therapeutic studies conducted on severe forms of SMA mice report 
such events when lifespan is increased.19, 20, 29, 30  There are few documented cases of SMA 
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type I patients with a single copy of SMN2 that have presented with finger necrosis, but the 
aetiology is unclear.31, 32  Parson’s group has demonstrated that the dense capillary bed of 
skeletal muscle is dramatically decreased in severe SMA mice, potentially exacerbating the 
already-affected muscle. This mechanism of capillary reduction may also explain necrosis in 
mild SMA mice,33  however the precise role of SMN protein in necrosis is not established, 
and may be due to a defect in innervations.34 Some oligonucleotide studies delay this necrosis 
phenotype via ICV injection, and a recent study demonstrated a rescue of necrosis following 
subcutaneous injection between P23 and P31 after the onset of tail-tip necrosis.17, 35  These 
data demonstrate that the phenotype can be rescued by central administration, but also that 
restoration of the periphery is achievable via systemic administration.36, 37 
A further peripheral consequence of SMA is its respiratory complications, generally linked to 
intercostal muscle weakness and thoracic cage deformation.26  In some patients atelectasis is 
reported,38, 39  and structural lung damage is observed after autopsy. In severe SMA mice lung 
abnormalities are also found.40  For the first time, in this study we have investigated 
respiratory function in type III SMA mice, and also report some dysfunction. Interestingly, 
TCI7 treatment restores some parameters of respiration, which could reflect the increased 
level of exon 7 re-inclusion in diaphragm. Given TCI7’s efficacy in the brain and spinal cord 
one cannot exclude the cause of this to restoring CNS control of respiration.  
As previously demonstrated in the mdx model, we show here that tcDNA has excellent uptake 
in cardiac muscle, with similar levels of exon re-inclusion to that of diaphragmatic tissue. 
Whilst cardiac issues are not particularly prevalent in SMA patients or mice models (save for 
congenital structural defects),41 SMA I patients with artificially prolonged lifespans have been 




Peripheral rescue of SMA may not be properly resolved by CNS administration alone, and 
tcDNA’s uptake profile across all tissues is a potential solution to this issue. That being said, 
other promising candidates which offer a similar uptake profile using systemic administration 
including vector- and AON-based strategies are currently under investigation.   
Many AAV vectors have been shown to efficiently cross the BBB,43 and as an example a 
group using self-complementary- adeno-associated vector serotype 9 (scAAV9) has 
demonstrated transduction efficacy throughout the spinal cord after a single systemic injection 
in newborn and adult mice and non-human primates, potentially surmounting the issue of 
peripheral vs. central treatment of SMA.44, 45 A clinical trial aiming at replacing SMN1 
directly, using these vectors is currently underway (ClinicalTrials.gov Identifier: 
NCT02122952). 
 However, the well-documented immunogenicity of the AAV capsid is likely to complicate 
repeated administration (if required) of such a therapy, not an issue with AON-based 
approaches. Combined treatments consisting of an initial AAV injection followed by 
sequential AON administration could be a viable treatment approach.  
Recently a peptide-conjugated PMO AON (Pip6a-PMO) has been administered intravenously 
in SMA mice at P0 and P2, achieving significant lifespan extension.46 More importantly, this 
group demonstrated corrected SMN2 transcripts in the CNS after tail vein administration at 
7.5 weeks, suggesting that this AON may penetrate the BBB. However, this was demonstrated 
in an asymptomatic mouse model, thus TCI7 is the only AON to demonstrate geno- and 
pheno-typic correction of central and peripheral SMA pathology with systemic administration 
as late as P7. Furthermore, the peptide moiety of Pip6a-PMO may be more likely to induce 
immunological reactions upon systemic administration vs. the naked chemistry of tcDNA, 
rendering clinical translation a lengthier and more complex process.  
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It is still debated how SMN deficiency leads to peripheral pathology, but the major goal of a 
tcDNA-based therapeutic strategy is to achieve systemic efficacy to ensure the best resolution 
of disease in SMA patients. TcDNA’s proven efficacy in restoring SMN2 exon 7 reinclusion 
in addition to its unique uptake profile and naked chemistry, offers these properties following 
less invasive administration, without the need for patient anaesthaesia. TcDNA could 
therefore represent a particularly attractive AON therapy for SMA requiring whole-body 
treatment.  
 
MATERIAL AND METHODS 
Cell culture and tcDNA transfection 
Human fibroblasts from a 3-year old type I SMA patient (GM03813, Coriell Cell 
Repositories) and wild type fibroblasts (GM03814, Coriell Cell Repositories) were grown in 
Dulbecco’s modified Eagle Medium with 20% foetal bovine serum and 1% penicillin-
streptomycin (100 U/ml). TcDNA AONs were synthetised by Synthena as previously 
described 47,48 and 2’OMePS were obtained  from Eurogentec. The two sequences used are 
SMN2 TSL (39;55) 5’-(pTTAATTTAAGGAATGTG)-3’ and SMN2 TCI7(10;24) 5’-
(pCTTTCATAATGCTGG)-3’. 
 2’OMePS and tcDNA transfection were performed with oligofectamine (Invitrogen) and 
incubated for 48 hours without serum and antibiotics.  
 




Total RNA was extracted 48 hours post-transfection using TRIzol reagent (Invitrogen) and 
first-strand cDNA synthesis was performed using Super Script II (Invitrogen) and random 
hexamers. PCR reactions were carried out with Master Mix 2x Phusion GC (Finnzymes) in a 
total volume of 50µL from 200ng cDNA, with 10µM each of the SMN-Ex6-FW (5’- 
GCTGATGCTTTGGGAAGTATGTTA-3’) and SMN-Ex8-Re primers (5’- 
ATTCCAGATCTGTCTGATCG-3‘). The PCR products were separated by electrophoresis on 
a 3% agarose gel. 
Real-time quantitative PCR reactions were run in Opticon2 (Biorad). cDNA was used as a 
template with primers specific for SMN and GAPDH, a housekeeping gene used as control 
for variations in the amount of template loaded to each reaction. The SMN primers, forward 
5’- GCTGATGCTTTGGGAAGTATGTTA-3’ in exon 6 and reverse 5’- 
CCTTAATTTAAGGAATGTGAGCACC -3’ in exon 7 were used. 20 ng of cDNA were 
included in a 20 µL-mix containing iTaq Universal SYBR© green supermix (Biorad) and 0,2 
µM of each specific primer. The run conditions were as follow: 15 min 95°C polymerase 
activation step, followed by 50 cycles of 2-step qPCR (15 sec of 95°C denaturation, 1 min of 
60°C combined annealing/extension) 
 
Western blot 
Fibroblast protein extracts were obtained in lysis buffer (10 mmol/l HEPES pH 7.9, 100 
mmol/l KCl, 1 mmol/l EDTA, 1 mmol/l 1,4-dithiothreitol, 1× complete protease inhibitor 
cocktail (Roche), 0.5% NP-40). Equal amounts of protein (determined by Bradford Protein 
Assay (Pierce)) were mixed with 2× loading buffer (125 mmol/l Tris pH 6.8, 2% sodium 
dodecyl sulfate, 10% glycerol, 0.01% bromophenol blue, 10% β-mercaptoethanol).25 10µg of 
protein of each sample were resolved by SDS-PAGE 4-12% Bis-Tris Gels (Invitrogen) and 
transferred onto a nitrocellulose membrane. The membrane was blocked with 10% milk in 
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Phosphate-Buffered Saline-Tween buffer. SMN immunoblot was performed overnight using 
rabbit polyclonal antibody SMN H-195 (dilution 1/500, Santa Cruz). A goat anti-rabbit 
secondary antibody conjugated with horseradish peroxidase was used to detect the protein 
SMN (dilution 1/50,000).  Signals were detected with the SuperSignal West Pico 
Chemiluminescent kit (ThermoScientific). The membrane was then washed, re-blocked and 
probed with mouse monoclonal anti-actin (dilution 1/5000, Sigma Aldrich) followed by a 
secondary sheep anti-mouse conjugated with horseradish peroxidase (dilution 1/15,000). The 
signal was detected as described earlier. Membranes were converted to numerical pictures by 
scanning and band intensities were analyzed using the ImageJ 1.46r software 




Transfected fibroblasts on slides were fixed with acetone/methanol (volume/volume). Fixed 
cells were blocked in PBS + 5% BSA for 1 hour. SMN immuno-staining was performed with 
rabbit polyclonal antibody SMN h-195 (dilution 1/100 in PBS +1% BSA) for 1 hour. Cells 
were washed in PBS and incubated with a secondary anti-rabbit Alexa 594. Then, cells were 
washed in PBS and incubated 5 minutes with DAPI (dilution 1/50,000). Slides were then 




All procedures were performed in accordance with national and European legislation. All 
mice experiments were carried out at the Centre d’évaluation fonctionnelle, Université Pierre 
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et Marie Curie, Paris, France. The initial breeding SMA type III model mice were purchased 
from Jackson Laboratory after MTA accordance, and were originally developed by Hsieh-Li 
et al.24 We used strain FVB.Cg- Tg(SMN2)2HungSMN1tm1Hung/J, founder line 2, stock 
number 005058. TC17 oligonucleotides were administered weekly to SMA mice by 
subcutaneous (Sc) injections at a dose of 200mg/kg/wk under general anaesthesia using 
isofluorane, starting at 7 days of age. Treated mice were sacrificed at various time points as 
indicated in the results section and muscles and tissues were harvested and snap-frozen in 
liquid nitrogen-cooled isopentane and stored at -80°C before further analysis.  
 
Respiratory function  
Mouse respiratory function was evaluated by whole-body plethysmography using an ‘EMKA 
Technologies’ plethysmograph as described by TREAT-NMD (http://www.treat-
nmd.eu/downloads/file/sops/dmd/MDX/DMD_M.2.2.002.pdf). Briefly, unrestrained 
conscious mice were placed in calibrated chambers containing a pneumatograph that 
measured pressure differentials within the compartment by a difference in air flow. Mice were 
allowed to acclimate in chambers for 45 min at a stable temperature and humidity. Data were 
then collected every 5s using ‘iox’ software (EMKA technologies). The inspiration time Ti 
was defined as the start of inspiration to the end of inspiration and the expiration time was 
defined as the start of expiration to the end of expiration. The relaxation time RT was defined 
as the time from the start of expiration to the time when 65% of the total expiratory pressure 
occurred. Pause and Penh were defined and calculated by the following formulas: Pause= (Te 
–RT)/RT and Penh= (PEP/PIP) x Pause, where PEP is peak expiratory pressure and PIP is 
peak inspiratory pressure. The value of each parameter was calculated from an average of 60 
recordings of 5 sec representing a total of 5 min. Inclusion criteria for each recording were > 8 





Data were analysed by GraphPad Prism5 software (San Diego, California, USA) and shown 
as the means ± S.E.M. “n” refers to the number of mice per group. Comparisons of statistical 
significance were assessed by unpaired student t-tests. Significant levels were set at *P < 
0.05, **P < 0.01, ***P < 0.001. 
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Figure 1: Evaluation of in vitro efficiency of tricyclo-DNA TCI7 
a) Detection of the inclusion of exon 7 of SMN2 mRNA by RT-PCR (primers on exons 6 and 
8) in patient SMA I fibroblasts. PCR products are visualized on 3% agarose gel (top) and 
quantified by imageJ (bottom). TCI7: fibroblasts treated with tcDNA AONs targeting the ISS-
N1, (SMAI) Untreated SMAI fibroblasts (GM03813 Coriell), (WT) healthy fibroblasts of 
mother (GM03814 Coriell). b) Detection of the SMN protein by Western blot in fibroblasts 
and normalisation with actin. Lane 1:  Untreated SMAI fibroblasts (GM03813 Coriell), Lane 
2: SMA fibroblasts treated with TCI7, Lane 3: healthy fibroblasts of mother (GM03814 
Coriell) Errors bars represent standard deviations. (*) p<0.05; (**) p<0.01. c) Detection of the 
SMN protein by immunostaining in untreated SMA fibroblasts (top) and SMA fibroblasts 
transfected with TCI7 (bottom). Cells were immunostained with the polyclonal antibody H-
SMN 195 (Santacruz). The red staining shows the expression of SMN protein in gems. Nuclei 
are labeled in blue (Dapi). Left panel: magnification x20; right panel: magnification x63. For 
magnification (x63), the apotome is used to see the gems in the nucleus. d) Counting of the 
gem number positive for SMN per nucleus (n=100 nuclei). The black bars correspond to 
untreated SMA type I, and grey to treated cells with TCI7. 
 
Figure 2: Evaluation of tricyclo-DNA TCI7 efficiency in SMA mice. 
Detection of the inclusion of exon 7 of SMN2 mRNA by RT-PCR in different tissues (a. 
Gastrocnemius, b. Diaphragm, c. Heart, d. Brain, e. Spinal cord) of SMA mice type III and 
quantification using Image J (bottom). (Un) untreated mice (n=3), (4wk) mice treated during 
4 weeks with 200 mg/kg/wk by subcutaneous injection and sacrificed 2 weeks after treatment 
(n=3), (12wk) mice treated during 12 weeks with 200 mg/kg/wk by subcutaneous injection 
and sacrificed 2 weeks after treatment (n=4).  
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Figure 3: Quantitative evaluation of exon 7 inclusion after tricyclo-DNA TCI7 treatment 
in SMA mice. 
Detection of the inclusion of exon 7 of SMN2 mRNA by qPCR in heart and brain of SMA 
type III mice. The primers used for amplification are located on exon 6 and 7 and normalized 
with GAPDH. (Un) untreated mice, (4wk) mice treated during 4 weeks with 200 mg/kg/wk by 
subcutaneous injection of TCI7, (12wk) mice treated during 12 weeks with 200 mg/kg/wk by 
subcutaneous injection of TCI7; n=3 per group. 
 
Figure 4: Sustained effect of tricyclo-DNA TCI7 treatment in SMA mice.  
Detection of the inclusion of exon 7 of SMN2 mRNA by RT-PCR in different tissues 
(Gastrocnemius, Diaphragm, Heart, Brain, Spinal cord) of SMA mice type III and 
quantification using Image J to evaluate the long term effect of tcDNA treatment. 
Black bars: untreated mice, grey bars mice treated during 4 weeks with 200 mg/kg/wk by 
subcutaneous injection and sacrified 2 weeks after treatment (called 4wk/2wk), dark grey bars 
mice treated during 4 weeks with 200 mg/kg/wk by subcutaneous injection and sacrified 10 
weeks after treatment (called 4wk/10wk). n = 3 per group; errors bars represent standard 
deviations. (*) p<0.05; (**) p<0.01. 
 





Respiratory function in SMA mice treated with 200 mg/kg of tcDNA for 12 weeks, compared 
to SMA control mice and WT mice (n = 4 per group).  Ti, Te, EIP, EEP, RT, f, penh are 
shown. Error bars are mean ± standard deviation. (*) p<0.05 compared with the saline 
controls. 
 
Figure 6: Phenotype rescue following tricyclo-DNA treatment in SMA mice. 
a)  Phenotypic rescue in type III SMA mice at 12 weeks of age after tcDNA treatment, 
compare to SMA control.  b) Toes and tails necrosis rescue in treated mice (right picture) 
compared to SMA control (left picture). c) Ears rescue in treated mice (right picture) compare 
to SMA control (left picture) d) Tails length of mice according to weeks. The darker grey 
curve corresponds to the size of the tails of type III SMA mice treated with TcI7 during 12 
weeks (n=4), the black curve is the size of the tails of type III SMA untreated mice (n=11) 
and the lighter grey one corresponds to the tails length of type III SMA mice treated with TcI7 
during 4 weeks only (n=3). 
 



























mean 129,6 180,8 2,9 1,9 0,2 0,2 109,5 44,4 205,5 1,2 19,9 0,444 
sem 7,18 50,45 0,30 0,33 0,03 0,03 37,71 8,68 20,47 0,17 4,37 0,061 
SMA 
mean 130,1 242,8 2,4 1,3 0,2 0,2 157,5 33,3 179,0 1,2 23,4 0,353 
sem 8,81 29,20 0,35 0,23 0,01 0,01 22,48 5,23 15,41 0,08 2,40 0,026 
p value 0,5130 0,0472 0,4490 0,0747 0,1816 0,2039 0,0423 0,1400 0,1136 0,8545 0,1899 0,0097
 
= + = = = = + - - = + - 
 
 






